« Commission on Human Medicines report on proposed permanent order to restrict the sale and supply of gonadotrophin-releasing hormone agonists in children and young people under 18 years of age for the purpose of puberty suppression in gender incongruence a | Main | NHS England annual accountability statement for NHS Public Health Functions Agreements 2022- 23 under Section 7A (s.7A) »

27/01/2025

Logo Kings Fund
If you prefer to receive this content via email, you can sign up to our twice-weekly bulletin here: https://www.kingsfund.org.uk/emails